E
Eric M. Paradise
Researcher at University of California, Berkeley
Publications - 11
Citations - 3754
Eric M. Paradise is an academic researcher from University of California, Berkeley. The author has contributed to research in topics: Artemisia annua & Mevalonate pathway. The author has an hindex of 8, co-authored 11 publications receiving 3470 citations. Previous affiliations of Eric M. Paradise include University of California.
Papers
More filters
Journal ArticleDOI
Production of the antimalarial drug precursor artemisinic acid in engineered yeast
Dae-Kyun Ro,Eric M. Paradise,Mario Ouellet,Karl Fisher,Karyn L. Newman,John M. Ndungu,Ho Kimberly,Eachus Rachel,Timothy S. Ham,James Kirby,Michelle C. Y. Chang,Sydnor T. Withers,Yoichiro Shiba,Richmond Sarpong,Jay D. Keasling +14 more
TL;DR: The engineering of Saccharomyces cerevisiae to produce high titres (up to 100 mg l-1) of artemisinic acid using an engineered mevalonate pathway, amorphadiene synthase, and a novel cytochrome P450 monooxygenase from A. annua that performs a three-step oxidation of amorpha-4,11-diene to art Artemisinic acid.
Journal ArticleDOI
Engineering of the pyruvate dehydrogenase bypass in Saccharomyces cerevisiae for high-level production of isoprenoids.
TL;DR: This work engineered the pyruvate dehydrogenase bypass in S. cerevisiae to enhance the supply of acetyl-CoA to the mevalonate pathway and achieve high-level production of amorphadiene and will be generally applicable to the production of a broad range of isoprenoids in yeast.
Journal ArticleDOI
High-level production of amorpha-4,11-diene in a two-phase partitioning bioreactor of metabolically engineered Escherichia coli.
Jack D. Newman,Jessica Marshall,Michelle C. Y. Chang,Farnaz Nowroozi,Eric M. Paradise,Douglas J. Pitera,Karyn L. Newman,Jay D. Keasling +7 more
TL;DR: This work reports on a strain of Escherichia coli containing a heterologous, nine‐gene biosynthetic pathway for the production of the terpene amorpha‐4,11‐diene, a precursor to the anti‐malarial drug artemisinin, and shows that amorphadiene evaporates from a fermentor with a half‐life of about 50 min.
Journal ArticleDOI
Induction of multiple pleiotropic drug resistance genes in yeast engineered to produce an increased level of anti-malarial drug precursor, artemisinic acid.
Dae-Kyun Ro,Mario Ouellet,Eric M. Paradise,Helcio Burd,Diana Eng,Chris J. Paddon,Jack D. Newman,Jay D. Keasling +7 more
TL;DR: The data presented here suggest that the engineered yeast producing artemisinic acid suffers oxidative and drug-associated stresses, and the use of plant-derived transporters and optimizing AMO activity may improve the yield of artemisic acid production in the genetically engineered yeast.
Journal ArticleDOI
Redirection of flux through the FPP branch-point in Saccharomyces cerevisiae by down-regulating squalene synthase.
TL;DR: The levels of these three metabolites were dependent not only upon the level of ERG9 repression, but also the timing of its repression relative to the induction of ADS and genes responsible for enhancing flux to FPP.